BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 36484700)

  • 1. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer.
    Liao L; Zhang YL; Deng L; Chen C; Ma XY; Andriani L; Yang SY; Hu SY; Zhang FL; Shao ZM; Li DQ
    Cancer Res; 2023 Feb; 83(3):471-484. PubMed ID: 36484700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paris saponin VII inhibits triple-negative breast cancer by targeting the MEK/ERK/STMN1 signaling axis.
    Zhang Y; Wei S; Zhang Q; Zhang Y; Sun C
    Phytomedicine; 2024 Jul; 130():155746. PubMed ID: 38763012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGA1 positively regulates the microtubule-destabilizing protein stathmin promoting motility in TNBC cells and decreasing tumour sensitivity to paclitaxel.
    Sgubin M; Pegoraro S; Pellarin I; Ros G; Sgarra R; Piazza S; Baldassarre G; Belletti B; Manfioletti G
    Cell Death Dis; 2022 May; 13(5):429. PubMed ID: 35504904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer.
    Liu XY; Jiang W; Ma D; Ge LP; Yang YS; Gou ZC; Xu XE; Shao ZM; Jiang YZ
    Theranostics; 2020; 10(24):10940-10956. PubMed ID: 33042263
    [No Abstract]   [Full Text] [Related]  

  • 5. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
    Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
    Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1.
    Li Y; Liang Y; Sang Y; Song X; Zhang H; Liu Y; Jiang L; Yang Q
    Cell Death Dis; 2018 Jan; 9(1):14. PubMed ID: 29323124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
    Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
    Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deubiquitinating enzyme USP9X regulates metastasis and chemoresistance in triple-negative breast cancer by stabilizing Snail1.
    Guan T; Yang X; Liang H; Chen J; Chen Y; Zhu Y; Liu T
    J Cell Physiol; 2022 Jul; 237(7):2992-3000. PubMed ID: 35506169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma.
    Bao P; Yokobori T; Altan B; Iijima M; Azuma Y; Onozato R; Yajima T; Watanabe A; Mogi A; Shimizu K; Nagashima T; Ohtaki Y; Obayashi K; Nakazawa S; Bai T; Kawabata-Iwakawa R; Asao T; Kaira K; Nishiyama M; Kuwano H
    Ann Surg Oncol; 2017 Dec; 24(13):4017-4024. PubMed ID: 28933054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma.
    Watanabe A; Suzuki H; Yokobori T; Tsukagoshi M; Altan B; Kubo N; Suzuki S; Araki K; Wada S; Kashiwabara K; Hosouchi Y; Kuwano H
    Cancer Sci; 2014 Jun; 105(6):690-6. PubMed ID: 24708177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP18 reduces paclitaxol sensitivity of triple-negative breast cancer via autophagy.
    Ge X; Zhang D; Song S; Mi Y; Shen Y; Jiang Q; Liang Y; Wang J; Ye Q
    Biochem Biophys Res Commun; 2022 Apr; 599():120-126. PubMed ID: 35180471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRAF6 promotes chemoresistance to paclitaxel of triple negative breast cancer via regulating PKM2-mediated glycolysis.
    Xu H; Li L; Dong B; Lu J; Zhou K; Yin X; Sun H
    Cancer Med; 2023 Oct; 12(19):19807-19820. PubMed ID: 37746908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.
    Deng L; Liao L; Zhang YL; Yang SY; Hu SY; Andriani L; Ling YX; Ma XY; Zhang FL; Shao ZM; Li DQ
    Sci Adv; 2024 Apr; 10(14):eadj4009. PubMed ID: 38569025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis.
    Han Z; Jia Q; Zhang J; Chen M; Wang L; Tong K; He W; Zhang Y; Zhu W; Qin J; Wang T; Liu T; Ma Y; Chen Y; Zha S; Zhang C
    J Exp Clin Cancer Res; 2023 Sep; 42(1):228. PubMed ID: 37667382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.
    Wei W; Zou Y; Jiang Q; Zhou Z; Ding H; Yan L; Yang S
    Int J Biol Markers; 2018 Jan; 33(1):102-108. PubMed ID: 28623645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
    Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
    Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.